Quantcast
Last updated on April 18, 2014 at 13:26 EDT

Latest Lexicon Pharmaceuticals Stories

2012-07-31 02:26:46

THE WOODLANDS, Texas, July 31, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and six months ended June 30, 2012. "Our positive top-line results from the Phase 2b study of LX4211 mark a very important milestone in the advancement of Lexicon's clinical pipeline towards late-stage...

2012-07-24 02:27:28

The Woodlands, Texas, July 24, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it will release its second quarter 2012 financial results on Tuesday, July 31, 2012 before the financial markets open. Lexicon management will hold a conference call and webcast to discuss financial results for the quarter and program status at 11:00 a.m. Eastern Time that same day. The dial-in number for the conference call is 888-645-5785 (within the US/Canada) or...

2012-06-29 02:23:52

THE WOODLANDS, Texas, June 29, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today the publication of results from two initial trials of LX4211 in patients with type 2 diabetes in the online edition of the journal Clinical Pharmacology & Therapeutics. The paper, containing results from both trials, is entitled, "LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients with Type 2 Diabetes in a Randomized, Placebo-controlled Trial," and will...

2012-06-25 02:25:43

THE WOODLANDS, Texas, June 25, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that LX4211, an investigational, oral, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2), showed substantial, dose-dependent, statistically-significant reductions in hemoglobin A1c (HbA1c) in a Phase 2b trial in patients diagnosed with poorly-controlled type 2 diabetes who were concurrently treated with metformin, an established diabetes therapy. LX4211...

2012-06-11 02:25:49

WINSTON-SALEM, N.C., June 11, 2012 /PRNewswire/ -- Tengion, Inc. (NASDAQ: TNGN), a leader in regenerative medicine, today announced continued clinical progress on key milestones for the ongoing Phase 1 trial of the Company's most advanced product candidate, the Neo-Urinary Conduit. "We are very pleased to report our continued progress executing on value creating milestones and believe that we are now in a position to accelerate enrollment in the Phase 1 trial of our Neo-Urinary Conduit. The...

2012-06-08 14:21:30

THE WOODLANDS, Texas, June 8, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will present six posters summarizing the mechanism of action and safety of LX4211, a dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2) currently in mid-stage development for type 2 diabetes, at the 72nd Scientific Sessions of the American Diabetes Association (ADA) in Philadelphia, Pennsylvania during the Saturday morning poster session on June 9, 2012....

2012-05-30 14:26:03

THE WOODLANDS, Texas, May 30, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Brian Zambrowicz, Ph.D., executive vice president and chief scientific officer, will present at the Jefferies 2012 Global Healthcare Conference on Wednesday, June 6 at 11:00 a.m. Eastern Time in New York City. Dr. Zambrowicz will provide an overview of Lexicon's clinical development programs and milestones. A live webcast of the presentation will be available through Lexicon's...

2012-05-18 02:24:42

SAN DIEGO, May 18, 2012 /PRNewswire/ -- Receptos Inc. today announced that company personnel will deliver a scientific podium presentation about RPC1063 at the Digestive Disease Week (DDW) annual meeting at 9 a.m. PDT on Sunday, May 20, 2012 at the San Diego Convention Center in San Diego, California. DDW attracts thousands of physicians, researchers, and academics from around the world to share the latest research in gastrointestinal health topics, for which DDW is the premier scientific...

2012-05-03 02:31:16

THE WOODLANDS, Texas, May 3, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that an independent, non-profit organization will provide funding to support the Phase 2 development of LX4211 in type 1 diabetes. LX4211, a dual inhibitor of sodium glucose transporter 1 and 2 (SGLT1 and SGLT2), was designed to improve control of blood glucose through mechanisms that do not require the pancreas to produce insulin. In type 1 diabetes, also called...

2012-05-03 02:30:59

SAN DIEGO, May 3, 2012 /PRNewswire/ -- Profil® Institute for Clinical Research, Inc., a company focused on early phase clinical trials for diabetes and obesity, announced today record growth in the number of clinical trials in the pipeline. Profil Institute also reports an increase in the number of mid-size biotech and off-shore clients, while maintaining active collaborations with the largest global pharmaceutical companies, driven by a strong demand for Phase I and metabolic disease...